Evolus (NASDAQ:EOLS) Stock Price Down 7.8%

Share on StockTwits

Evolus Inc (NASDAQ:EOLS) shares dropped 7.8% during trading on Wednesday . The company traded as low as $12.33 and last traded at $12.70, approximately 1,543,000 shares changed hands during mid-day trading. An increase of 103% from the average daily volume of 759,870 shares. The stock had previously closed at $13.78.

EOLS has been the topic of a number of research reports. ValuEngine raised Evolus from a “hold” rating to a “buy” rating in a research note on Monday, November 4th. Zacks Investment Research raised Evolus from a “sell” rating to a “hold” rating in a research note on Tuesday, October 15th. JMP Securities dropped their price objective on Evolus from $35.00 to $30.00 and set a “market outperform” rating on the stock in a research note on Tuesday, August 13th. They noted that the move was a valuation call. Mizuho reissued a “buy” rating and issued a $30.00 price objective on shares of Evolus in a research note on Thursday, September 5th. Finally, Leerink Swann initiated coverage on Evolus in a research note on Tuesday, November 26th. They issued an “outperform” rating and a $25.00 price objective on the stock. One research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $26.36.

The company has a current ratio of 3.66, a quick ratio of 3.28 and a debt-to-equity ratio of 4.53. The firm has a market capitalization of $424.50 million, a price-to-earnings ratio of -8.09 and a beta of 4.44. The stock has a fifty day moving average of $14.90 and a 200-day moving average of $15.53.

Evolus (NASDAQ:EOLS) last issued its earnings results on Monday, November 4th. The company reported ($0.78) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.33) by $0.55. The company had revenue of $13.17 million during the quarter, compared to analyst estimates of $5.18 million. As a group, equities research analysts forecast that Evolus Inc will post -3.75 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of EOLS. BB&T Securities LLC purchased a new position in shares of Evolus during the second quarter valued at $160,000. Prime Capital Investment Advisors LLC purchased a new position in shares of Evolus during the second quarter valued at $44,000. Point72 Asset Management L.P. purchased a new position in shares of Evolus during the second quarter valued at $4,167,000. HighTower Advisors LLC purchased a new position in shares of Evolus during the second quarter valued at $175,000. Finally, Ladenburg Thalmann Financial Services Inc. grew its holdings in shares of Evolus by 2,224.0% during the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,324 shares of the company’s stock valued at $34,000 after buying an additional 2,224 shares in the last quarter. Institutional investors and hedge funds own 16.94% of the company’s stock.

About Evolus (NASDAQ:EOLS)

Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

Featured Story: Are sell-side analysts objective?

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Clean Yield Group Lowers Stock Holdings in Quest Diagnostics Inc
Clean Yield Group Lowers Stock Holdings in Quest Diagnostics Inc
Clean Yield Group Decreases Stock Position in General Electric
Clean Yield Group Decreases Stock Position in General Electric
Clean Yield Group Grows Stock Holdings in iShares Core S&P Mid-Cap ETF
Clean Yield Group Grows Stock Holdings in iShares Core S&P Mid-Cap ETF
iShares Agency Bond ETF  Shares Bought by Clean Yield Group
iShares Agency Bond ETF Shares Bought by Clean Yield Group
Clean Yield Group Has $452,000 Position in First Solar, Inc.
Clean Yield Group Has $452,000 Position in First Solar, Inc.
Clean Yield Group Buys 2,884 Shares of AFLAC Incorporated
Clean Yield Group Buys 2,884 Shares of AFLAC Incorporated


 
© 2006-2020 Zolmax.